SCHEMBL30837877

SCHEMBL30837877

COc1ccc(Cn2c(=O)c3cc(OC(CF)CF)c(F)cc3n(C3CCN(C=O)CC3)c2=O)cc1OC

nearest known ligand 0.80

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PDE7A Q13946 10/20 0.80
▸ PDE7B Q9NP56 5/20 0.80
▸ PDE8A O60658 3/20 0.80
▸ SMN1; SMN2 Q16637 3/20 0.37
▸ POLB P06746 2/20 0.37
▸ TP53 P04637 1/20 0.37
▸ C5AR1 P21730 5/20 0.36
▸ NPSR1 Q6W5P4 2/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ SIGMAR1 Q99720 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ CRHBP P24387 1/20 0.35
▸ CRHR2 Q13324 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL101100 1.00 PDE7A (0.80) PDE7APDE7BPDE8ASMN1; SMN2POLB
SCHEMBL101156 0.96 PDE7A (0.74) PDE7APDE7BPDE8ASMN1; SMN2POLB
SCHEMBL100388 0.95 PDE7A (0.72) PDE7APDE7BPDE8APOLBTSHR
SCHEMBL100920 0.94 PDE7A (0.71) PDE7APDE7BPDE8ASMN1; SMN2POLB
SCHEMBL101006 0.93 PDE7A (0.70) PDE7APDE7BPDE8ASMN1; SMN2POLB
SCHEMBL30837768 0.93 PDE7A (0.70) PDE7APDE7BPDE8ASMN1; SMN2POLB
SCHEMBL101155 0.93 PDE7A (0.70) PDE7APDE7BPDE8ASMN1; SMN2POLB
SCHEMBL100992 0.93 PDE7A (0.70) PDE7APDE7BPDE8APOLBC5AR1
SCHEMBL101247 0.93 PDE7A (0.70) PDE7APDE7BPDE8ASMN1; SMN2POLB
SCHEMBL101023 0.93 PDE7A (0.70) PDE7APDE7BPDE8ASMN1; SMN2C5AR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4572765-A1 USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE Mitodicure GmbH (DE) 2025-06-25 — — EP disclosed
WO-2024038089-A1 USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE MITODICURE GMBH (DE) 2024-02-22 — — WO disclosed
Send feedback